| Sep 16 |
BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID
|
| Sep 3 |
BioVie gets FDA okay for Phase 2 study for long COVID drug
|
| Sep 3 |
BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID
|
| Aug 27 |
BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting
|
| Aug 13 |
BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting
|
| Aug 8 |
BioVie says FDA aligns with mid-stage Parkinson’s disease trial
|
| Aug 8 |
BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’s Disease
|
| Aug 6 |
BioVie announces 1-for-10 reverse stock split
|
| Aug 6 |
BioVie Inc. Announces Reverse Stock Split
|
| Aug 6 |
Individual investors invested in BioVie Inc. (NASDAQ:BIVI) copped the brunt of last week's US$55m market cap decline
|
